INTRODUCTION: Cefiderocol is a new siderophore cephalosporin designed to be active against extensively resistant Gram-negative bacteria; however, clinical studies are limited to complicated urinary tract infections, pneumonia, and intra-abdominal infections. To date, no data are available on neurosurgical site infections. CASE PRESENTATION: We present a case of a patient successfully cured with Cefiderocol for a neurosurgical site infection due to extensively resistant P. aeruginosa, who had failed a previous treatment based on combined antimicrobial therapy and right parietal bone excision. CONCLUSIONS: Cefiderocol is a promising antibiotic for complicated infections due to multidrug resistant gram-negative bacteria.
INTRODUCTION:Cefiderocol is a new siderophore cephalosporin designed to be active against extensively resistant Gram-negative bacteria; however, clinical studies are limited to complicated urinary tract infections, pneumonia, and intra-abdominal infections. To date, no data are available on neurosurgical site infections. CASE PRESENTATION: We present a case of a patient successfully cured with Cefiderocol for a neurosurgical site infection due to extensively resistant P. aeruginosa, who had failed a previous treatment based on combined antimicrobial therapy and right parietal bone excision. CONCLUSIONS:Cefiderocol is a promising antibiotic for complicated infections due to multidrug resistant gram-negative bacteria.
Authors: Pasquale Sansone; Luca Gregorio Giaccari; Francesco Coppolino; Caterina Aurilio; Alfonso Barbarisi; Maria Beatrice Passavanti; Vincenzo Pota; Maria Caterina Pace Journal: Antibiotics (Basel) Date: 2022-07-06
Authors: Cristina Marcelo; Alejandro de Gea Grela; María Martínez Palazuelos; Javier Veganzones; David Grandioso; Beatriz Díaz-Pollán Journal: Open Forum Infect Dis Date: 2022-08-01 Impact factor: 4.423